Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
221
resultados
Última actualización
01/05/2026 [07:09:00]
Resultados 75 a 100 de 221
Resumen de: US20260108537A1
This disclosure describes a cannabinoid-based nanoplatform for treating shingles, designed to enhance bioavailability and controlled release of active ingredients. The composition includes cannabinoids like cannabidiol (CBD) and cannabigerol (CBG), alongside flavonoids, polyphenols, and alkaloids, in oral and topical formulations. The oral capsule combines cannabinoids with polyphenols and flavonoids to provide systemic anti-inflammatory, antiviral, and neuroprotective effects, particularly for nerve pain and inflammation, including postherpetic neuralgia. The topical cream includes cannabinoids, capsaicin, and aloe vera, offering localized relief from pain, itching, and rash. The method targets both systemic and localized symptoms during the acute phase of shingles, aiming to inhibit varicella-zoster virus replication, disrupt viral assembly, and prevent viral release, while also providing immune modulation and anti-inflammatory benefits. The nanoplatform uses nano-emulsification techniques, producing particles smaller than 200 nm to ensure optimal delivery and therapeutic efficacy, offering comprehensive relief for shingles symptoms.
Resumen de: WO2026082030A1
Provided in the present invention is an ionizable lipid compound. Specifically, the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof. Further provided in the present invention are a nanoparticle pharmaceutical composition containing the compound, and the use of the compound and composition thereof in the delivery of nucleic acids.
Resumen de: WO2026083169A2
The present invention relates to natural nanocarriers or nanoparticles with biocompatible, biodegradable, hypoallergenic, environmentally and physiologically acceptable properties. More in particular, it can be stated that the present invention relates to natural biopolymer nanocarriers, nanoparticles or nano-spheres with biocompatible, biodegradable, environmentally and physiologically acceptable properties as vehicles for physiological and environmentally safe delivery of active ingredients. The present invention also relates to nanoparticle compositions, methods of making the nanoparticles and nanoparticles compositions, as well as uses thereof.
Resumen de: WO2026083241A1
The present disclosure provides ionizable lipids that are particularly beneficial in formulations of lipid nanoparticles providing advantageous improvements in the delivery of nucleic acids to hepatic stellate cells with enhanced efficiency. The ionizable lipids are N,N-substituted hydroxylamine ester compound. The disclosure also provides lipid nanoparticles, pharmaceutical compositions, and methods including the provided ionizable lipids.
Resumen de: US20260108472A1
0000 Disclosed are methods and compositions for restoring Cyr61 in bone tissue. In certain aspects, the compositions comprise a recombinant Cyr61 carried in carbon nanotubes. The compositions may be used for various methods including restoring Cyr61 expression in bone, increasing bone density, or treating a bone disease in a patient.
Resumen de: US20260109984A1
0000 Therapeutic methods, systems, and compositions for treating a patient suffering from hemoglobinopathy include treating the patient to increase expression of noncoding RNA activated by DNA damage (NORAD). Overexpression of NORAD long non-coding RNA leads to an increase in fetal hemoglobin expression. The hemoglobinopathy may be β-thalassemia or sickle cell disease.
Resumen de: AU2026202508A1
Methods are disclosed for treating a subject with a disorder, such as, but not limited to, a) fibrosis of an organ or tissue; b) solid organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia. These methods include selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63loCD81lo. In additional embodiments, methods are disclosed for increasing myoblast differentiation. pr p r
Resumen de: WO2026085291A1
Disclosed herein are metabolizable binary gold supraclusters, which, in some implementations, comprise cationic gold nanoclusters laden with a therapeutic nucleic acid, such as a small interfering RNA (siRNA), and are intertwined through bioresponsive crosslinkers within a hydrophilic polymer matrix. Also provided herein are uses of the supraclusters, e.g., in treatment of diseases such as cancers.
Resumen de: WO2026085498A1
The present disclosure provides compositions and methods for enhancing gene editing. In some aspects, the compositions and methods are used prevent the progression or treat diseases such as osteoarthritis and other joint disorders that are characterized by an inflammatory component.
Resumen de: WO2026085500A1
Provided herein are compositions and methods for ablating intracellular signaling through specific cell surface receptors as means of treatment for various conditions of a pro-inflammatory character. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint. In some aspects, the compositions and method are for treating or preventing localized nociception, inflammation, degeneration, or morphological changes associated with back or spine conditions or disorders.
Resumen de: WO2026081389A1
The present invention relates to the field of pharmaceutical technology, and in particular, to a daptomycin nano-FORMULATION, a method for preparing same, and use thereof. The method comprises: A, encapsulating daptomycin with a copolymer poly(lactic-co-glycolic acid) to give a nanoparticle (NP); and B, sonicating a cell membrane vesicle overexpressing RANK and the nanoparticle (NP) in a water bath for 3 min, and then sequentially extruding the mixture through polycarbonate membranes of 800 nm, 400 nm, and 200 nm to give the daptomycin nano-formulation. The weight ratio of the membrane protein to PLGA is 0.25. By the method of the present invention, a daptomycin nano-formulation targeting rheumatoid arthritis is successfully prepared. The daptomycin nano-formulation prepared by the present invention has good stability. The daptomycin nano-formulation of the present invention has good therapeutic effects against RA.
Resumen de: US20260108633A1
0000 An application for the EGT-AuNPs in preparing contrast agents and/or antioxidants is provided, where the EGT-AuNPs include gold nanoparticles (AuNPs), the AuNPs are connected to L-ergothioneine (EGT) by gold-sulfur bonds, and the antioxidants include medicines for preventing and/or treating acute kidney injury (AKI). EGT-AuNPs with antioxidant activity are designed and synthesized through the combination of the higher imaging contrast of gold and the antioxidant natural product EGT, and they are ultra-small AuNPs, which achieve the combination of CT imaging and antioxidant effects, and are suitable for renal imaging, particularly for the early diagnosis and treatment of AKI, realizing the integration of diagnosis and treatment, circumventing the toxicity of contrast agents present in the conventional nanomaterials, lowering the serum creatinine and urea nitrogen levels, and reducing the degree of renal tubular damage.
Resumen de: US20260108883A1
The present invention relates to a microfluidic device for preparing lipid nanoparticles capable of delivering nucleic acids, and a method for preparing lipid nanoparticles using the same. Using the microfluidic device, lipid nanoparticles having a desired size can be prepared by adjusting the molar ratio of compositions and the Reynolds number.
Resumen de: US20260108597A1
0000 The present invention relates to an antibody mRNA for treating SARS-coronavirus-2 delta infection and a composition including same, the composition exhibiting excellent therapeutic efficacy against SARS-coronavirus-2 delta infection.
Resumen de: US20260108462A1
0000 The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.
Resumen de: US20260108503A1
Micelle compositions comprising a hedgehog pathway inhibitor and their use in treating skin diseases, conditions, or disorders, such as skin cancers, including basal cell carcinoma, are disclosed.
Resumen de: US20260108627A1
Compositions and methods are described herein for treating subjects having hypercholesterolemia and/or cardiovascular disease.
Resumen de: US20260108656A1
The present invention relates to a levan-catechol composite, and a tissue adhesion composition and nanocluster, including same. In particular, the levan-catechol composite is prepared by the conjugation of levan and catechol and is applicable, by hydrogelation or nanoclustering thereof, for use in tissue adhesion in wet environments, wound healing, hemostasis, or drug delivery.
Resumen de: US20260109732A1
Provided are lipid amine compounds which are useful in the preparation of lipid nanoparticle compositions for delivery of therapeutic or prophylactic payload into cells.
Resumen de: US20260108615A1
0000 The present invention relates to a mucoadhesive polymeric prodrug comprising a partially succinated polyvinyl alcohol (PVA-SA) with adjusted amount of hydroxyl and carboxyl pendant groups, which form an ester and/or amide linkage with amino and/or carboxyl and/or hydroxyl groups of biologically active compounds such as proteins, peptides, synthetic chemical, or natural products compounds (e.g. doxorubicin as an antitumor agent and antifibrotic drug). Preferably, said biologically active compounds are cysteamine (CYS) as the aminothiol compound and one compound selected from the group consisting of doxorubicin (DOX), ketoprofen (KETO), or 4-hydroxybenzyl alcohol (HBA). Moreover, the simultaneous presence of both hydroxyl and carboxyl groups in the partially succinated polyvinyl alcohol (PVA-SA) chain of the prodrug enables the self-assembled formation of 50-260 nm particles from the linear macromolecules and thus the drug release can be prolonged or adjusted. The present invention also relates to improving the mucoadhesive properties of the polymeric prodrug by the regulation of the amount of conjugated aminothiol compound. Further, the present invention relates to the method for producing said mucoadhesive polymeric prodrug, and nanoparticles of the said mucoadhesive polymeric prodrug.
Resumen de: WO2026082012A1
The present invention provides a drug-loaded nanoparticle composition suitable for drug delivery in vivo, wherein the drug-loaded nanoparticle composition is formed in the form of a non-covalent bond and comprises an active ingredient, cyclodextrin, and albumin. Drug-loaded nanoparticles or the composition thereof in the present invention are stable in a solution state, avoiding cumbersome operations of reconstitution and redissolution. Compared with a known freeze-dried powder of nanoparticles containing albumin, the nanoparticles in the present invention have a particle size of less than 150 nm, can remain stable for at least 7 days or more without change, and can be predicted to be stable for a long time.
Resumen de: WO2026082183A1
Disclosed in the present invention is a lyoprotectant for nucleic acid-lipid nanoparticles. The lyoprotectant of the present invention is formed by combining sucrose or trehalose with polyvinylpyrrolidone in a specific ratio, and provides a good lyoprotective effect for the nucleic acid-lipid nanoparticles, ensuring that there is no significant difference in particle size, uniformity, encapsulation efficiency, nucleic acid integrity, and expression performance of the nucleic acid-lipid nanoparticles before and after lyophilization. Furthermore, by adjusting the salt concentration in a mixed solution of the nucleic acid-lipid nanoparticles and the lyoprotectant, the lyoprotective effect on the nucleic acid-lipid nanoparticles is further improved, so that the performance of lyophilized nucleic acid-lipid nanoparticles is closer to that before lyophilization.
Resumen de: WO2026084314A1
The present invention relates to: lipid nanoparticles with improved genetic material delivery efficiency through the regulation of an extracellular matrix and pH control of intracellular organelles; and use thereof. A composition for delivering a genetic material, according to the present invention, comprises lipid nanoparticles and a proton pump inhibitor, whereby the genetic material can be effectively delivered by overcoming various intracellular and extracellular barriers and the limitations of existing delivery systems.
Resumen de: WO2026085319A1
The present disclosure relates, in one aspect, to degradable ionizable lipid compounds of formula (I). In another aspect, the disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid of formula (I). In another aspect, the disclosure provides methods of the LNPs of the disclosure for splenic delivery of therapeutic cargo.
Nº publicación: US20260109976A1 23/04/2026
Solicitante:
RNAV8 BIO INC [US]
Resumen de: US20260109976A1
0000 Provided herein are heterologous engineered mRNA molecules; and methods of making and using said synthetic engineered mRNAs to increase expression profiles.
BOPI
Sede Electrónica
